Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin plus cadonilimab in HER2-overexpressing advanced gastric cancer
NCT06492317Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin and cadonilimab in gastric cancer (GC) and gastroesophageal junction cancer, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Objective Response Rate at 6 months. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
disitamab vedotincadonilimab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT06492317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06492317.